Source: https://www.kcl.ac.uk From: news-medical.net Researchers from the School of Basic & Medical Biosciences have identified a potential target that could lead to new treatments for triple negative breast cancer. One in five patients with breast cancer are diagnosed with triple negative breast cancer, a cancer type where tumour cells don’t have receptors for oestrogen and progesterone, or the Her2 protein. …
How a Cancer Doctor Really Feels About Second Opinions
Commentary By: Andrew C. Neuschatz, MD From: medscape.com As a radiation oncologist in private practice, the question of getting a second opinion comes up fairly regularly with patients during consults. My standard answer to patients is that they shouldn’t trust any doctor who is afraid of a second opinion. I’ll admit, however, that the topic of second opinions is probably …
Researchers Suggest Current Methods for Reporting Toxicities in Cancer Clinical Trials are Falling Short
Findings published in JNCCN examine the differences between patient- and clinician-reported outcomes; recommend a greater focus on the cumulative effect of multiple low-level toxicities. New research from Europe, published in the December 2018 issue of JNCCN—Journal of the National Comprehensive Cancer Network, finds that quality-of-life for people with cancer is reduced by an accumulation of low-level toxicities just as much …
NCCN Patient Advocacy Summit Examines Disparities in Cancer Care and Explores Solutions
Advocates, patients, providers, and other experts share perspectives on the challenges that prevent equitable opportunities and outcomes for people with cancer. The National Comprehensive Cancer Network® (NCCN®) hosted a Patient Advocacy Summit in Washington, D.C., today, focused on advocating for equity in cancer care. The summit included case studies, presentations, and panel discussions, all highlighting the barriers that prevent various …
CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic
Source: CytRx Corporation From: prnewswire.com CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its private, wholly-owned subsidiary Centurion BioPharma Corporation (the Company) has concluded the pre-clinical phase of its development for its albumin binding ultra high potency LADR™ (Linker Activated Drug Release) drug candidates, LADR-7, LADR-8, LADR-9 and LADR-10, and for its unique …
The Responsibility of Doctors to Motivate Their Cancer Patients
View PostBacteria-Based Drug Delivery System Outperforms Conventional Methods
By: Virginia Tech From: labmanager.com A new drug delivery system could radically expand cancer treatment options An interdisciplinary team of three Virginia Tech faculty members affiliated with the Macromolecules Innovation Institute has created a drug delivery system that could radically expand cancer treatment options. The conventional cancer treatment method of injecting nanoparticle drugs into the bloodstream results in low efficacy. …
CytRx Corporation Highlights Aldoxorubicin Included in New NantCell Inc. Triple Negative Breast Cancer Clinical Trial
News provided by: CytRx Corporation From: prnewswire.com This New Trial Represents the Third NantCell Study Evaluating Aldoxorubicin Combined with Immunotherapy or Cell-Based Therapy CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a …
Researchers Use 3D Printing to Isolate Aggressive Breast Cancer Cells
By: Clare Scott From: 3dprint.com Researchers at the University of Girona have successfully isolated stem cells from one of the most aggressive forms of breast cancer – using 3D printing. The goal of isolating the cells is to find a drug that attacks them exclusively, without damaging healthy parts of the body. According to Dr. Teresa Puig, Director of the Oncology …
Diabetes and hypertension drug combo kills cancer cells
By: Ana Sandoiu From: medicalnewstoday.com New research, published in the journal Cell Reports, finds a drug combination that kills cancer cells by depleting them of energy. Metformin is a common drug in the fight against type 2 diabetes. It lowers blood sugar by slowing the release of glucose from the liver and the absorption of sugar from food in the …